Kevin Chin
COSA-IPOS Joint Scientific Meeting 2012
Days
Tuesday, 13th November
Wednesday, 14th November
Thursday, 15th November
Tracks
The Best of the Best
Trials in Progress
General Psycho-Oncology
Clinical Issues, Case reports and Service delivery
Search
Speakers
Kevin Chin
Abstracts this author is presenting:
Four-year survival update for metastatic melanoma (MM) patients (pts) treated with ipilimumab (IPI) + dacarbazine (DTIC) on phase 3 study CA184-024
—
COSA Best of the Best Posters: Translational Research
Five-year survival rates for patients (pts) with metastatic melanoma (MM) treated with ipilimumab (IPI) in phase II trials
—
COSA Posters: Clinical Research
Safety of ipilimumab in patients (pts) with untreated, advanced melanoma alive beyond 2 years: Results from a phase III study
—
COSA Posters: Clinical Research